Company Description

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States.

Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.

The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library.

Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.

Enveric Biosciences, Inc.

Country	United States
Founded	1994
Industry	Biotechnology
Sector	Healthcare
Employees	6
CEO	Joseph Tucker

Contact Details

Address: 245 First Street, Riverview II Cambridge, Massachusetts 02142 United States
Phone	617 444 8400
Website	enveric.com

Stock Details

Ticker Symbol	ENVB
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	890821
CUSIP Number	29405E505
ISIN Number	US29405E5050
Employer ID	95-4484725
SIC Code	2834

Key Executives

Name	Position
Dr. Joseph Edward Tucker Ph.D.	Chief Executive Officer and Director
Kevin M. Coveney CPA	Chief Financial Officer
Dr. Peter J. Facchini Ph.D.	Chief Innovation Officer

Latest SEC Filings

Date	Type	Title
May 4, 2026	D	Notice of Exempt Offering of Securities
Apr 30, 2026	8-K	Current Report
Apr 30, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2026	EFFECT	Notice of Effectiveness
Apr 29, 2026	424B3	Prospectus
Apr 23, 2026	S-3	Registration statement under Securities Act of 1933
Apr 20, 2026	8-K	Current Report
Apr 14, 2026	ARS	Filing
Apr 14, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 14, 2026	DEF 14A	Other definitive proxy statements

View All SEC Filings